PUBLISHED FOR OPPOSITION
on 22 Oct 2024
Last Applicant/ Owned by
Box 30089 SE-200 61 Limhamn
SE
Serial Number
79378524 filed on 05th May 2023
Registration Number
N/A
Correspondent Address
Bethany J. Whelan
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Logo Mark Trademark Information
Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucleotide manufacturing Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes Advertising services; business administration; business management; providi Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucleotide manufacturing
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [035]
Advertising, Business & Retail Services
Advertising services; business administration; business management; providing office function
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [040]
Treatment & Processing of Materials Services
Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [003]
Cosmetics and Cleaning Products
Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79378524
Mark Type
No Service Mark
Attorney Docket Number
No CONI111TM66
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Design Code(s)
01.09.05 -
Atoms or molecular models
Legal History
| Status Date | Action Taken |
|---|---|
| 22nd Oct 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 22nd Oct 2024 | PUBLISHED FOR OPPOSITION |
| 02th Oct 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 16th Sep 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 16th Sep 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 16th Sep 2024 | EXAMINERS AMENDMENT -WRITTEN |
| 16th Sep 2024 | EXAMINER'S AMENDMENT ENTERED |
| 16th Sep 2024 | EXAMINERS AMENDMENT E-MAILED |
| 28th Aug 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 28th Aug 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |